CClinicalTrials.gg
Sign In
CompletedNCT01183247SterFreePlusUpdated Aug 17, 2010

An Open, Single Centre, Randomised, Parallel Group Study to Investigate Three Different Immunosuppressive Regimens

A Phase 4 interventional study of Rapamycin and Everolimus in Comparative Study and Immunosuppressive Agents, sponsored by University Hospital, Basel, Switzerland. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-08-17.

Sponsored by University Hospital, Basel, Switzerland · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

An open, single center, randomised study to investigate three different immunosuppressive regimens for de novo renal transplant recipients:

  1. st sirolimus / EC-MPS / tacrolimus regimen

    • After 3 months a protocol biopsy is performed. If no rejection is detected the calcineurin inhibitor (tacrolimus) is withdrawn.

  2. nd everolimus / EC-MPS / tacrolimus regimen

    • After 3 months a protocol biopsy is performed. If no rejection is detected the calcineurin inhibitor (tacrolimus) is withdrawn.
  3. rd tacrolimus / EC-MPS / prednisone regimen - After 3 months a protocol biopsy is performed. If no rejection is detected prednisone is withdrawn.
Read the detailed description

This study is designed to show similar efficacy but a different adverse event profile between the three regimens. Its main purpose is to provide more information, if steroid free immunosuppressive treatment is a valuable alternative in the treatment of de novo kidney transplant recipients and that it is possible to withdraw calcineurin inhibitors after 3 months in this steroid free protocol. A secondary rationale of the study is to compare sirolimus with everolimus directly to better differentiate these two mTOR-inhibitors in terms of compound-specific effects and class-effects. This should allow for early conclusions on the usage of these two mTOR-inhibitors in CNI-free regimens.

Basis for this study are the following hypotheses regarding the first 6 months of treatment following kidney transplantation:

  • Similar graft function in the three treatment groups after 6 months
  • No difference in graft and patient survival in the three groups
  • No differences in incidence of first, total number, type of acute rejections, and number of anti-rejection treatments in the three groups
  • No differences in number of patients successfully withdrawn from calcineurin inhibitor in the sirolimus and everolimus arm, respectively
  • A different adverse event profile with regard to the incidence of dyslipidemias, impaired fasting glucose, new onset diabetes mellitus, de novo post-transplant insulin dependency, histological signs of calcineurin inhibitor toxicity, and tubulointerstitial nephrotoxicity in the three groups. In addition to this the incidence of mTOR-inhibitor specific adverse events will be analysed.

These hypotheses are the basis for the study objectives.

02

Conditions studied

  • Comparative Study
  • Immunosuppressive Agents

Keywords

  • Everolimus,
  • rapamycin,
  • prednisone,
  • tacrolimus,
  • MMF,
  • steroid-free,
  • protocol biopsy
03

In context

Lead sponsor

University Hospital, Basel, Switzerland is the lead sponsor of 968 studies on the registry; 191 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Male or female patients between 18 and 75 years of age, regardless of race.
  2. Female patients of child bearing age agree to maintain effective birth control practice during the study.
  3. Patient has end stage kidney disease and is a suitable candidate for primary renal transplantation or retransplantation as assessed by the transplantation centre.
  4. Patient has been fully informed and has given written or independent person witnessed oral informed consent.

Exclusion criteria

Exclusion Criteria:

  1. in Patient is pregnant or breastfeeding.
  2. Patient has a low immunological risk constellation, defined by receiving a kidney from a HLA-identical related living donor.
  3. Patient has a high immunological risk constellation, defined as having donor specific HLA-antibodies and/or having a previous graft survival shorter than 3 years due to rejection.
  4. Patient and donor have a positive T or B-cell crossmatch.
  5. Patient and donor are ABO incompatible.
  6. Age of donor > 75 years.
  7. Cold ischemia time > 36 hours.
  8. Patient has leucopenia, defined as having at transplantation less than 3000/mm3 leukocytes.
  9. Patient has thrombocytopenia, defined as having at transplantation less than 75000/mm3 thrombocytes.
  10. Patient is allergic or intolerant to cremophor RH 60 or structurally related compounds, steroids, everolimus, tacrolimus, Sirolimus or EC-MPS.
  11. Patient or donor is known to be HIV positive.
  12. Patient has significant liver disease, defined as having during the past 28 days continuously ASAT (SGOT) and/or ALAT (SGPT) levels greater than 3 fold of the upper value of the normal range of the investigational site.
  13. Patient with malignancy or history of malignancy ≤ 2 years, except non metastatic basal or squamous cell carcinoma of the skin that has been treated successfully.
  14. Patient has significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting, or active peptic ulcer.
  15. Patient is taking or has been taking an investigational drug in the past 28 days.
  16. Patient has previously received or is receiving another organ transplant other than kidney.
  17. Patient is unlikely to comply with the visits schedule the protocol.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Active comparator
    Rapamycin

    Rapamycin-MMF-tacrolimus

    Drug: Rapamycin

  • Active comparator
    Everolimus

    Everolimus - tacrolimus - MMF

    Drug: Everolimus

  • Active comparator
    Prednisone

    tacrolimus - MMF -prednisone

    Drug: Prednisone

Interventions

  • DrugRapamycin

    Add rapamycin de novo to tacrolimus and MMF

    Also known as: Sirolimus

  • DrugEverolimus

    Add everolimus de novo to tacrolimus and MMF

  • DrugPrednisone

    Add prednisone de novo to tacrolimus and MMF

06

What researchers measure

Primary outcomes

  1. Plasma creatinine and creatinine clearance (Cockcroft-Gault) after 6 months of treatment

    Time frame: 6 months

07

Study locations

1 site
  • Clinic for transplantation immunology and nephrology
    Basel, 4031, Switzerland
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 17, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01183247
Lead sponsor
University Hospital, Basel, Switzerland
Collaborators
Novartis
First posted
Aug 17, 2010
Start date
Jul 2008
Primary completion
Jun 2010
Completion
Jun 2010
Last update
Aug 17, 2010

Study contacts

Juerg U Steiger, Professor
principal investigator · University Hospital, Basel, Switzerland

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

University Hospital, Basel, Switzerland

Start the discussion